Results 211 to 220 of about 32,925 (256)

Significantly Lower CYP2D6 Metabolism Measured as the O/N-Desmethylvenlafaxine Metabolic Ratio in Carriers of CYP2D6*41 Versus CYP2D6*9 or CYP2D6*10: A Study on Therapeutic Drug Monitoring Data From 1003 Genotyped Scandinavian Patients [PDF]

British Journal of Clinical Pharmacology, 2019
Aims CYP2D6*9, CYP2D6*10 and CYP2D6*41 are the most frequent reduced-function CYP2D6 alleles in Caucasians. Despite lacking in vivo evidence, they are collectively classified with an enzyme activity score of 0.5.
Espen Molden, Erik Eliasson, Marin M Jukic   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

The Impact of the CYP2D6 “Enhancer” Single Nucleotide Polymorphism on CYP2D6 Activity

Clinical Pharmacology & Therapeutics, 2021
rs5758550 has been associated with enhanced transcription and suggested to be a useful marker of CYP2D6 activity. As there are limited and inconsistent data regarding the utility of this distant “enhancer” single nucleotide polymorphism (SNP), our goal was to further assess the impact of rs5758550 on CYP2D6 activity toward two probe substrates ...
Jean C, Dinh, Erin C, Boone, Vincent S, Staggs, Robin E, Pearce, Wendy Y, Wang, Roger, Gaedigk, James Steven, Leeder, Andrea, Gaedigk   +7 more
openaire   +2 more sources

Understanding CYP2D6 interactions

Drug Discovery Today, 2009
Owing to the polymorphic nature of CYP2D6, clinically significant issues can arise when drugs rely on that enzyme either for clearance, or metabolism to an active metabolite. Available screening methods to determine if the compound is likely to cause drug-drug interactions, or is likely to be a victim of inhibition of CYP2D6 by other compounds will be ...
Marcel J, de Groot, Florian, Wakenhut, Gavin, Whitlock, Ruth, Hyland   +3 more
openaire   +2 more sources

Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors

Journal of Neural Transmission, 2014
The cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of most antidepressants. Comedication with a potent CYP2D6 inhibitor can convert patients with extensive metabolizer (EM) or ultra-rapid metabolizer (UM) genotypes into poor metabolizer (PM) phenotypes.
F, Gressier, C, Verstuyft, P, Hardy, L, Becquemont, E, Corruble   +4 more
openaire   +2 more sources

CYP2D6*36 GENE ARRANGEMENTS WITHIN THE CYP2D6 LOCUS: ASSOCIATION OF CYP2D6*36 WITH POOR METABOLIZER STATUS

Drug Metabolism and Disposition, 2006
Unexplained cases of CYP2D6 genotype/phenotype discordance continue to be discovered. In previous studies, several African Americans with a poor metabolizer phenotype carried the reduced function CYP2D6*10 allele in combination with a nonfunctional allele.
Andrea, Gaedigk, L Dianne, Bradford, Sarah W, Alander, J Steven, Leeder   +3 more
openaire   +2 more sources

Genotyping of CYP2D6 in Parkinsons's Disease

cclm, 2000
Abstract Parkinson's disease is characterized by progressive degradation of dopaminergic neurons. Cytochrome P450 CYP2D6 enzyme is one of the most investigated and highly polymorphic isoforms, which metabolizes many drugs and is also involved in the metabolism of dopamine.
Gergorec-Koršić, Marta, Šimundić, Ana-Maria, Topić, Elizabeta, Štefanović, Mario, KORŠIĆ, MARTA   +4 more
openaire   +3 more sources

Inhibition of CYP2D6 Activity by Bupropion

Journal of Clinical Psychopharmacology, 2005
The purpose of this study was to assess the effect of bupropion on cytochrome P450 2D6 (CYP2D6) activity. Twenty-one subjects completed this repeated-measures study in which dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release (150 mg twice daily) or matching ...
Michael, Kotlyar, Lisa H, Brauer, Timothy S, Tracy, Dorothy K, Hatsukami, Jennifer, Harris, Carrie A, Bronars, David E, Adson   +6 more
openaire   +2 more sources

Implementation of CYP2D6 genotyping in psychiatry

Expert Opinion on Drug Metabolism & Toxicology, 2009
Response to pharmacotherapy is subject to large inter-individual variation. Most medicine is metabolised by CYP450 enzymes, including CYP2D6. CYP2D6 activity is determined substantially by the genetic composition. Polymorphisms of CYP2D6 are associated with inadequate response on treatment with psychotropics. The large number of polymorphisms of CYP2D6
Harriët M, Loovers, Jan, van der Weide
openaire   +2 more sources

The Decreased in Vivo Clearance of CYP2D6 Substrates by CYP2D6*10 Might Be Caused Not Only by the Low-Expression but Also by Low Affinity of CYP2D6

Archives of Biochemistry and Biophysics, 2000
CYP2D6 exhibits genetic polymorphism with interindividual differences in metabolic activity. We have found a significant influence on the pharmacokinetics of venlafaxine by the CYP2D6*10 allele in a Japanese population. CYP2D6.10, which is translated from CYP2D6*10, has two amino acid substitutions: Pro34 --> Ser and Ser486 --> Thr.
Junichi Azuma, Yoshihiko Funae, J Azuma
exaly   +3 more sources

Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4

European Journal of Clinical Pharmacology, 1998
After liver transplantation (LT), genotypic differences between the recipient and the transplanted liver, medications and post-LT complications may all affect drug metabolism. We have studied the effect of two CYP2D6 mutations in the donor and the recipient on post-LT CYP2D6 phenotype.The CYP2D6 phenotype was assessed in 48 patients before and after LT
O, Monek, G, Paintaud, Y, Bechtel, J P, Miguet, G, Mantion, P R, Bechtel   +5 more
openaire   +2 more sources